- Home
- LYEL vs ADCT Comparison
LYEL vs ADCT Comparison
Compare LYEL & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- ADCT
- Stock Information
- Founded
- LYEL 2018
- ADCT 2011
- Country
- LYEL United States
- ADCT Switzerland
- Employees
- LYEL N/A
- ADCT N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- ADCT Health Care
- Exchange
- LYEL Nasdaq
- ADCT Nasdaq
- Market Cap
- LYEL 207.7M
- ADCT 241.0M
- IPO Year
- LYEL 2021
- ADCT 2020
- Fundamental
- Price
- LYEL $0.44
- ADCT $3.09
- Analyst Decision
- LYEL Sell
- ADCT Strong Buy
- Analyst Count
- LYEL 2
- ADCT 5
- Target Price
- LYEL $1.00
- ADCT $7.75
- AVG Volume (30 Days)
- LYEL 627.4K
- ADCT 694.8K
- Earning Date
- LYEL 05-13-2025
- ADCT 05-14-2025
- Dividend Yield
- LYEL N/A
- ADCT N/A
- EPS Growth
- LYEL N/A
- ADCT N/A
- EPS
- LYEL N/A
- ADCT N/A
- Revenue
- LYEL $65,000.00
- ADCT $75,817,000.00
- Revenue This Year
- LYEL N/A
- ADCT $9.19
- Revenue Next Year
- LYEL N/A
- ADCT $16.27
- P/E Ratio
- LYEL N/A
- ADCT N/A
- Revenue Growth
- LYEL N/A
- ADCT 10.49
- 52 Week Low
- LYEL $0.39
- ADCT $1.05
- 52 Week High
- LYEL $2.80
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- LYEL 51.63
- ADCT 79.62
- Support Level
- LYEL $0.39
- ADCT $1.83
- Resistance Level
- LYEL $0.43
- ADCT $2.35
- Average True Range (ATR)
- LYEL 0.03
- ADCT 0.30
- MACD
- LYEL 0.00
- ADCT 0.13
- Stochastic Oscillator
- LYEL 83.39
- ADCT 98.92
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).